At the 6th Herbsttreffen AG Molekularpathologie in Karlsruhe, Germany, from 21th to 22th November 2016, GILUPI will be one of the exhibitors and sponsors of the event. The medical device company will be presenting its current product, the GILUPI CellCollector, to an interested audience.
Liquid biopsy – isolating and analyzing circulating tumor cells (CTCs) from the blood of cancer patients – can provide additional information on prognosis of patients, treatment efficacy, resistance and molecular tumor evolution. Whereas CTCs represent the liquid phase of current tumor progression, cell free tumor DNA is apoptotic/necrotic cell material representing past cell death. CTC detection is challenging due to their extremely low frequency amongst millions of leucocytes and billions of red blood cells. The advanced GILUPI technology allows for the detection and characterization of CTCs combined with the proof of the malignant origin of the cells. The tumor cells are captured in vivo with high sensitivity and selectivity providing compelling and improved diagnostic use for personalized medicine, early diagnostic and clinical monitoring.
You are invited to visit our exhibition booth at the 6th Herbsttreffen AG Molekularpathologie. For further information on this congress, see http://www.pathologie-dgp.de/.